Maximal Cytoreduction in Patients With FIGO Stage IIIC to Stage IV Ovarian, Fallopian, and Peritoneal Cancer in Day-to-Day Practice: A Retrospective French Multicentric Study
- 1 October 2012
- journal article
- research article
- Published by BMJ in International Journal of Gynecologic Cancer
- Vol. 22 (8), 1337-1343
- https://doi.org/10.1097/igc.0b013e31826a3559
Abstract
ObjectivesTo evaluate the outcome of maximal cytoreductive surgery in patients with stage IIIC to stage IV ovarian, tubal, and peritoneal cancer regarding overall survival (OS) and disease-free survival (DFS).Materials and MethodsFive hundred twenty-seven patients with stage IIIC (peritoneal) and stage IV (pleural) ovarian, fallopian tube, and peritoneal carcinoma underwent surgery between January 2003 and December 2007 in 7 gynecologic oncology centers in France. Patients undergoing primary and interval debulking surgery were included, whichever the number of chemotherapy cycles. The extent of disease, type of surgical procedure, and amount of residual disease were recorded. A multivariate analysis of the outcome was performed, taking into account the stage, grade, and timing of surgery.ResultsMedian DFS was 17.9 months, but median OS was not reached at the time of analysis. Complete cytoreductive surgery, without evident residual tumor at the end of the procedure, was obtained in 71% of all patients (primary surgery, 33%). After neoadjuvant therapy, the rate of complete debulking surgery was higher (74%) compared to primary cytoreductive surgery (65%). Twenty-three percent of patients needed “ultra radical surgery” to achieve this goal. The most significant predictive factor for DFS and OS was complete cytoreductive surgery compared to any amount, even minimal (1–10 mm), of residual disease. In the group of patients with complete cytoreductive surgery, the patients undergoing surgery before chemotherapy showed better DFS than those having first chemotherapy.ConclusionThe findings confirm that complete cytoreduction is the criterion standard of surgery in the management of advanced ovarian, peritoneal, and fallopian tube cancer, whatever the timing of surgery. With experienced teams, surgery was completed, without evident residual tumor in 71% of the cases.Keywords
This publication has 16 references indexed in Scilit:
- Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigmGynecologic Oncology, 2009
- Pulmonary morbidity of diaphragmatic surgery for stage III/IV ovarian cancerBJOG: An International Journal of Obstetrics and Gynaecology, 2009
- Incidence and management of pancreatic leaks after splenectomy with distal pancreatectomy performed during primary cytoreductive surgery for advanced ovarian, peritoneal and fallopian tube cancerGynecologic Oncology, 2009
- The impact of bulky upper abdominal disease cephalad to the greater omentum on surgical outcome for stage IIIC epithelial ovarian, fallopian tube, and primary peritoneal cancerGynecologic Oncology, 2008
- The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC–IV epithelial ovarian cancerGynecologic Oncology, 2006
- Ovarian cancer in Europe: Cross-sectional trends in incidence and mortality in 28 countries, 1953-2000International Journal of Cancer, 2004
- Prise en charge chirurgicale des tumeurs épithéliales malignes de l’ovaireJournal de Chirurgie, 2004
- Complete Cytoreductive Surgery Is Feasible and Maximizes Survival in Patients with Advanced Epithelial Ovarian Cancer: A Prospective StudyGynecologic Oncology, 1998
- The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume Stage III epithelial ovarian cancer: A gynecologic oncology group studyGynecologic Oncology, 1992
- Stage III epithelial ovarian cancer: The role of maximal surgical reductionGynecologic Oncology, 1984